The European Crohn’s and Colitis Organisation maintains the global "gold standard" for IBD guidelines, with new 2025 updates for Paediatric UC and GRADE-based Crohn's treatments . ECCO Guidelines - European Crohn's and Colitis Organisation
Offers detailed clinical practice guidelines for Crohn's Disease , including the French Recommendations for Crohn's Practice (PDF) . Download Nouvelles recommandations dans les MICI pdf
The latest clinical guidelines for (Maladies Inflammatoires Chroniques de l'Intestin), specifically Crohn's Disease (MC) and Ulcerative Colitis (RCH), focus on early intervention, "treat-to-target" strategies, and the integration of new-generation biological therapies like Skyrizi . Key Updates in MICI Management (2024–2026) Key Updates in MICI Management (2024–2026) Guidelines now
Guidelines now shift away from the traditional "step-up" approach. Clinicians are encouraged to initiate advanced therapies (biologics or small molecules) earlier for moderate-to-severe cases to prevent irreversible tissue damage. Newer agents such as IL-23 antagonists (e
Provides patient-centered updates and the AFAMAG 2025 Management Report (PDF) which discusses emerging "combiotherapy" strategies.
Newer agents such as IL-23 antagonists (e.g., Skyrizi) and JAK inhibitors have been integrated into the 2025 treatment algorithms.
The British Society of Gastroenterology 2025 Guidelines provide a comprehensive roadmap for both medical and surgical management.